PE20142443A1 - Sal de l-malato de derivados de 2,7-diaza-espiro[4,5]dec-7-ilo y formas cristalinas de los mismos como agonistas del receptor de grelina - Google Patents
Sal de l-malato de derivados de 2,7-diaza-espiro[4,5]dec-7-ilo y formas cristalinas de los mismos como agonistas del receptor de grelinaInfo
- Publication number
- PE20142443A1 PE20142443A1 PE2014001906A PE2014001906A PE20142443A1 PE 20142443 A1 PE20142443 A1 PE 20142443A1 PE 2014001906 A PE2014001906 A PE 2014001906A PE 2014001906 A PE2014001906 A PE 2014001906A PE 20142443 A1 PE20142443 A1 PE 20142443A1
- Authority
- PE
- Peru
- Prior art keywords
- diaza
- spiro
- dec
- methyl
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261642116P | 2012-05-03 | 2012-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20142443A1 true PE20142443A1 (es) | 2015-01-28 |
Family
ID=48626496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001906A PE20142443A1 (es) | 2012-05-03 | 2013-05-02 | Sal de l-malato de derivados de 2,7-diaza-espiro[4,5]dec-7-ilo y formas cristalinas de los mismos como agonistas del receptor de grelina |
Country Status (20)
Country | Link |
---|---|
US (1) | US20130296358A1 (zh) |
EP (1) | EP2852591A1 (zh) |
JP (1) | JP2015525202A (zh) |
KR (1) | KR20150003771A (zh) |
CN (1) | CN104271579A (zh) |
AR (1) | AR093748A1 (zh) |
AU (1) | AU2013255458A1 (zh) |
BR (1) | BR112014026210A2 (zh) |
CA (1) | CA2867043A1 (zh) |
CO (1) | CO7111286A2 (zh) |
CU (1) | CU20130159A7 (zh) |
EA (1) | EA201491990A1 (zh) |
IL (1) | IL235215A0 (zh) |
MA (1) | MA20150428A1 (zh) |
PE (1) | PE20142443A1 (zh) |
PH (1) | PH12014502446A1 (zh) |
SG (1) | SG11201405810UA (zh) |
TN (2) | TN2013000441A1 (zh) |
TW (1) | TW201348235A (zh) |
WO (1) | WO2013164790A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3074923A1 (en) * | 2017-09-28 | 2019-04-04 | Biogen Inc. | Novel salts |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE288444T1 (de) | 1995-05-29 | 2005-02-15 | Pfizer | Dipeptide, die die ausschüttung von wachstumshormonen stimulieren |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
WO1997011697A1 (en) | 1995-09-26 | 1997-04-03 | Merck & Co., Inc. | 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone |
WO1997044042A1 (en) | 1996-05-22 | 1997-11-27 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
AU7445498A (en) | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
US6329342B1 (en) | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
IL142047A0 (en) | 1998-10-02 | 2002-03-10 | Sibia Neurosciences Inc | Mglur5 antagonists for the treatment of pain and anxiety |
US6194578B1 (en) | 1998-11-20 | 2001-02-27 | Pfizer Inc. | Dipeptide derivatives |
EP1486498A1 (en) | 1998-11-23 | 2004-12-15 | Pfizer Products Inc. | Process and intermediates for growth hormone secretagogues |
GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
DOP2001000154A (es) | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
IL143690A0 (en) | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
SK11952003A3 (sk) | 2001-03-26 | 2004-03-02 | Novartis Ag | Deriváty pyridínu, spôsoby ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
ATE459598T1 (de) | 2001-05-14 | 2010-03-15 | Novartis Ag | Sulfonamidderivate |
JP3894035B2 (ja) | 2001-07-04 | 2007-03-14 | 東レ株式会社 | 炭素繊維強化基材、それからなるプリフォームおよび複合材料 |
TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
WO2003087036A1 (en) | 2002-04-10 | 2003-10-23 | Eli Lilly And Company | Stereoselective process for the synthesis of (d)-2-amino-5-phenylpentanoic or alkyl ester thereof |
US6696468B2 (en) | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
SE0201940D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New combination II |
DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
AR042206A1 (es) | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
GB0302876D0 (en) | 2003-02-07 | 2003-03-12 | Novartis Ag | Organic compounds |
EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
JP2004277319A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1−(4−ピペリジニルメチル)ピペリジニルアミド誘導体およびそれを含有する医薬組成物 |
JP2004277318A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1−(1−置換カルボニル−4−ピペリジニルメチル)ピペリジン誘導体およびそれを含有する医薬組成物 |
EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
JP2007501821A (ja) | 2003-08-12 | 2007-02-01 | エフ.ホフマン−ラ ロシュ アーゲー | Cfrアンタゴニストとしてのテトラヒドロキナゾリン誘導体 |
WO2005013997A1 (en) | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
WO2005068448A1 (en) | 2003-08-29 | 2005-07-28 | Ionix Pharmaceuticals Limited | Sulfonamides antagonising n-type calcium channels |
CA2537916A1 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
ES2377484T3 (es) | 2003-09-03 | 2012-03-28 | Pfizer, Inc. | Compuestos de bencimidazolona que tiene actividad agonista del receptor 5-HT |
WO2005023806A2 (en) | 2003-09-05 | 2005-03-17 | Neurogen Corporation | Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
JP2005082508A (ja) | 2003-09-05 | 2005-03-31 | Dainippon Pharmaceut Co Ltd | 2−アルコキシ−6−アミノ−5−ハロゲノ−n−(1−置換−4−ピペリジニル)ピリジン−3−カルボキサミド誘導体およびそれを含有する医薬組成物 |
US20070027156A1 (en) | 2003-09-09 | 2007-02-01 | Hisao Nakai | Crf antagonists and heterobicyclic compounds |
GB0322612D0 (en) | 2003-09-26 | 2003-10-29 | Novartis Ag | Organic compounds |
JP2005104896A (ja) | 2003-09-30 | 2005-04-21 | Dainippon Pharmaceut Co Ltd | 2−アルコキシ−6−アミノ−5−ハロゲノピリジン−3−カルボキサミド誘導体およびそれを含有する医薬組成物 |
JP2007507514A (ja) | 2003-09-30 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノキサリン化合物 |
EP1673348B1 (en) | 2003-09-30 | 2009-04-01 | Janssen Pharmaceutica N.V. | Benzoimidazole compounds |
JP4842829B2 (ja) | 2003-10-31 | 2011-12-21 | 武田薬品工業株式会社 | 含窒素縮合複素環化合物 |
BRPI0416319A (pt) | 2003-11-10 | 2007-01-09 | Merck & Co Inc | composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas |
US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
US7211568B2 (en) | 2003-12-18 | 2007-05-01 | Kosan Biosciences Incorporated | 9-Desoxoerythromycin compounds as prokinetic agents |
JP2005206590A (ja) | 2003-12-25 | 2005-08-04 | Mitsubishi Pharma Corp | ナトリウムチャネルサイト2選択的阻害剤 |
WO2005068461A1 (en) | 2004-01-07 | 2005-07-28 | Aryx Therapeutics | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
BRPI0507180A (pt) | 2004-01-29 | 2007-06-26 | Pfizer | derivados de 1-isopropil-2-oxo-1,2-diidropiridina-3-carboxamida tendo atividade agonìstica de receptor 5-ht4 |
TW200533348A (en) | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
EP1574478A1 (de) | 2004-03-08 | 2005-09-14 | Solvay Fluor GmbH | Herstellung von Carbonylfluorid |
UA89226C2 (en) | 2004-03-25 | 2010-01-11 | Янссен Фармацевтика Н.В. | Imidazole compounds |
EP1732564A1 (en) | 2004-03-29 | 2006-12-20 | Merck & Co., Inc. | Biaryl substituted pyrazinones as sodium channel blockers |
TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
EP1734820A4 (en) | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands |
GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
AU2005254800B2 (en) | 2004-06-15 | 2010-12-09 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
SE0401653D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
WO2006023757A2 (en) | 2004-08-19 | 2006-03-02 | University Of Virginia Patent Foundation | Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents |
GB0420424D0 (en) | 2004-09-14 | 2004-10-20 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
ES2332808T3 (es) | 2004-11-05 | 2010-02-12 | Theravance, Inc. | Compuestos agonistas del receptor 5-ht4. |
EP1807423B1 (en) | 2004-11-05 | 2009-05-20 | Theravance, Inc. | Quinolinone-carboxamide compounds |
JP2008519794A (ja) | 2004-11-11 | 2008-06-12 | アージェンタ・ディスカバリー・リミテッド | ピリミジン化合物 |
US20060111416A1 (en) | 2004-11-24 | 2006-05-25 | Lane Charlotte A L | Octahydropyrrolo[3,4-C]pyrrole derivatives |
RU2404179C2 (ru) | 2004-12-22 | 2010-11-20 | Тереванс, Инк. | Индазол-карбоксамидные соединения |
EP1818061A1 (en) | 2005-12-02 | 2007-08-15 | Charite-Universitätsmedizin Berlin | Use of ghrelin for stimulating hair growth |
AU2008241532A1 (en) | 2007-02-09 | 2008-10-30 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
US7994203B2 (en) | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
AR086554A1 (es) * | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
-
2013
- 2013-05-02 EP EP13729090.4A patent/EP2852591A1/en not_active Withdrawn
- 2013-05-02 BR BR112014026210A patent/BR112014026210A2/pt active Search and Examination
- 2013-05-02 JP JP2015509556A patent/JP2015525202A/ja active Pending
- 2013-05-02 TW TW102115769A patent/TW201348235A/zh unknown
- 2013-05-02 MA MA37470A patent/MA20150428A1/fr unknown
- 2013-05-02 CN CN201380023253.4A patent/CN104271579A/zh active Pending
- 2013-05-02 US US13/875,556 patent/US20130296358A1/en not_active Abandoned
- 2013-05-02 SG SG11201405810UA patent/SG11201405810UA/en unknown
- 2013-05-02 AU AU2013255458A patent/AU2013255458A1/en not_active Abandoned
- 2013-05-02 KR KR20147030325A patent/KR20150003771A/ko not_active Application Discontinuation
- 2013-05-02 CA CA2867043A patent/CA2867043A1/en not_active Abandoned
- 2013-05-02 EA EA201491990A patent/EA201491990A1/ru unknown
- 2013-05-02 WO PCT/IB2013/053492 patent/WO2013164790A1/en active Application Filing
- 2013-05-02 PE PE2014001906A patent/PE20142443A1/es not_active Application Discontinuation
- 2013-05-06 AR ARP130101532A patent/AR093748A1/es unknown
- 2013-10-29 TN TNP2013000441A patent/TN2013000441A1/fr unknown
- 2013-11-27 CU CU2013000159A patent/CU20130159A7/es unknown
-
2014
- 2014-09-23 TN TNP2014000400A patent/TN2014000400A1/fr unknown
- 2014-10-20 IL IL235215A patent/IL235215A0/en unknown
- 2014-10-27 CO CO14237477A patent/CO7111286A2/es unknown
- 2014-10-31 PH PH12014502446A patent/PH12014502446A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12014502446A1 (en) | 2015-01-12 |
KR20150003771A (ko) | 2015-01-09 |
TN2013000441A1 (en) | 2015-03-30 |
TW201348235A (zh) | 2013-12-01 |
AU2013255458A1 (en) | 2014-10-09 |
CU20130159A7 (es) | 2014-02-28 |
IL235215A0 (en) | 2014-12-31 |
CA2867043A1 (en) | 2013-11-07 |
EP2852591A1 (en) | 2015-04-01 |
CO7111286A2 (es) | 2014-11-10 |
MA20150428A1 (fr) | 2015-11-30 |
US20130296358A1 (en) | 2013-11-07 |
WO2013164790A1 (en) | 2013-11-07 |
AR093748A1 (es) | 2015-06-24 |
SG11201405810UA (en) | 2014-11-27 |
EA201491990A1 (ru) | 2015-02-27 |
JP2015525202A (ja) | 2015-09-03 |
BR112014026210A2 (pt) | 2017-06-27 |
CN104271579A (zh) | 2015-01-07 |
TN2014000400A1 (en) | 2015-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000058A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol utiles para usar como inhibidores del transportador de sodio-glucosa | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
CL2013000787A1 (es) | Compuestos derivados de benzamida fusionada sustituida, moduladores del receptor de bradiquininas; composición farmaceutica, utiles en el tratamiento del dolor agudo, visceral, neuropatico, inflamacion de la piel, entre otras. | |
EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
CL2008001994A1 (es) | Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras. | |
CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
CL2008002111A1 (es) | Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras. | |
CL2011001176A1 (es) | Compuestos octahidrociclopenta[c]pirrol-4-amina sustituidos, bloqueadores de los canales de calcio; composicion farmaceutica; y su uso en el tratamiento del dolor, tal como dolor agudo, dolor cronico y dolor neuropatico y para trastornos del sistema nervioso central tales como accidente cerebrovascular y epilepsia, entre otros. | |
PA8852901A1 (es) | Inhibidores de proteina cinasa | |
DOP2011000183A (es) | Polimorfos de(s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c][1,2-oxaborol-1-ol | |
CL2009000697A1 (es) | Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras. | |
EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
CR9891A (es) | Ciclopropil aminas como moduladores del receptor de histamina h3 | |
CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
CL2009001345A1 (es) | Compuestos derivados de 1-piridin-2-il-urea y 1-pirimidin-2-il-urea sustituidos, inhibidores de adn girasa y topoisomerasa iv; composicion farmaceutica; y su uso en tratamiento de infecciones bacterianas como neumonia adquirida intrahospitalariamente, infecciones a la piel, bronquitis, sinusitis, entre otras enfermedades. | |
BR112013012117A2 (pt) | sistema de distribuição de fármacos iontoforético coempacotado autocontido ativado por usuário | |
BR112015007503A2 (pt) | derivados de oxazolina terapeuticamente ativos | |
PE20110589A1 (es) | Formas cristalinas del compuesto (r)-5-((e)-2-(pirrolidin-3-ilvinil)pirimidina | |
PE20142443A1 (es) | Sal de l-malato de derivados de 2,7-diaza-espiro[4,5]dec-7-ilo y formas cristalinas de los mismos como agonistas del receptor de grelina | |
RU2011103476A (ru) | Нифуртимокс для лечения болезней, вызванных трихомонадидами | |
CL2015001409A1 (es) | Forma cristalina anhidra de (1,1-dioxo-hexahidro-1lambda*6*-tiopiran-4-il)-{(s)-3-[1-(6-metoxi-5-metil-piridin-3-il)-2,3-dihidro-1h-pirido[3,4-b][1,4]oxazin-7-iloxi]-pirrolidin-1-il}-metanona; composicion farmaceutica; uso en el tratamiento de trastornos autoinmunes, inflamatorios, alergicos, rechazo de trasplantes, entre otros. | |
CL2008001615A1 (es) | Compuestos derivados de di(hetero)aril-ciclohexano; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cardiopatias, arritmias, isquemias, entre otras. | |
UA111837C2 (uk) | Фармацевтична композиція |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |